Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Featured
EMA backs extending Mounjaro to children with type-2 diabetes
On 11 December 2025 the EMA's CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.
Latest
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
BPC-157 and night sweats: what we know
Night sweats appear in BPC-157 user reports but not in any published study. Here is what the evidence and the likely mechanism actually show.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
GLP-1R G protein bias via ECL3 displacement
A July 2026 Cell Reports study shows N-terminal modifications to GLP-1R agonists shift signalling toward G protein by displacing extracellular loop 3.
Semaglutide, NAION, and a retracted study
A 2025 paper in Retina on semaglutide and optic nerve risk has been retracted without a stated reason, complicating an already contested safety debate.
Skin Growths, Sermorelin, and BPC-157/TB500
Community reports link sermorelin and BPC-157/TB-500 use to acanthosis. Here is what the IGF-1 and skin-biology literature actually shows.
T2D and obesity: why treatment falls short
A July 2026 expert review finds clinicians undertreat obesity in type 2 diabetes, leaving a key driver of glycaemic failure and cardiovascular risk unaddressed.
Tirzepatide and kidney function in obesity
A 36-person real-world study found three months of tirzepatide improved eGFR in adults with obesity, with BMI change explaining about 19% of the kidney benefit.
Tirzepatide and platelet volume in obesity
A 60-person retrospective study found tirzepatide reduced mean platelet volume 0.94 fL with a 3.92 BMI-unit drop. What the data shows and where it falls short.
Tirzepatide vs GLP-1 agonists: MACE in T2D
A July 2026 JAHA study found tirzepatide linked to 25% lower MACE risk versus GLP-1 agonists in 16,402 matched patients with type-2 diabetes and ASCVD.
Retatrutide in Sweden: no approval yet
Retatrutide holds no EMA or Läkemedelsverket authorisation as of July 2026. Here is where the TRIUMPH trials stand and what that means for Swedish patients.
Semax in Sweden: regulatory status
Semax has no marketing authorisation in Sweden or the EU. Here is the Läkemedelslagen framework, what changed in 2025-2026, and who to ask.
Categories
Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Comparison
Peptide-vs-peptide, country-vs-country, label-vs-grey-market. Methodology disclosed, conclusions tied to primary sources.
Vendor accountability
Counterfeit warnings, supply-chain incidents, Certificates of Analysis read in detail. We do not sell peptides and we do not promote vendors; we hold them to the same evidence bar as everyone else.
Methodology
How we score evidence depth, source recency and safety clarity. Behind-the-scenes editorial decisions. The reasoning, not just the result.
Country deep-dive
Single-country regulatory or market reports. How peptides actually move through Danish customs; what the BfArM said about a specific schedule shift; the German press response to a Mounjaro shortage.